• Calixa Therapeutics Inc. is an innovative
biopharmaceutical company dedicated to the
clinical development of novel anti-infective
products. Calixa's most advanced product
candidate is CXA-101 (FR264205), a novel,
broad-spectrum cephalosporin antibiotic
with excellent activity against Pseudomonas
aeruginosa, including drug-resistant isolates.
